Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin-cyclophosphamide plus atezolizumab dose-finding study in advanced breast and gynecologic cancers
NL-OMON45572Phase 1Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carboplatin, cyclophosphamide and atezolizumab in breast cancer, ovarian cancer, Cervical Cancer (CC) and 1 more, sponsored by Netherlands Cancer Institute. Started Feb 2017; status: recruiting.
02
Drugs
carboplatincyclophosphamideatezolizumab
03
Conditions
breast cancerovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON45572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45572.